Immix Biopharma, Inc reports results for the quarter ended December 31 - Earnings Summary

• Immix Biopharma, Inc IMMX.OQ reported a quarterly adjusted loss of 28 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -16 cents. The mean expectation of three analysts for the quarter was for a loss of 16 cents per share. Wall Street expected results to range from -21 cents to -10 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Immix Biopharma, Inc's reported EPS for the quarter was a loss of 28 cents​.

• The company reported a quarterly loss of $10.69 million.

• Immix Biopharma, Inc shares had risen by 63.9% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 2.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Immix Biopharma, Inc is $14.00, about 36.4% above its last closing price of $8.91

This summary was machine generated from LSEG data March 26 at 12:57 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)